On 27 April 2026, Sun Pharmaceutical Industries Limited and Organon & Co announced that they have entered into a definitive agreement for the acquisition by Sun Pharma of all outstanding shares of Organon in an all-cash transaction valued at US$11.75 billion.
The transaction is expected to close in early 2027, subject to closing conditions including regulatory approvals and Organon stockholder approval. The transaction will be “effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger”.
According to the companies, the acquisition of Organon will result in Sun Pharma being among the top 25 global pharmaceutical companies with combined revenue of US$12.4 billion and will enable Sun Pharma’s entry into biosimilars as a “Top 10 global player”.
Biosimilars in Organon’s portfolio include Brenzys® (etanercept), Hadlima® (adalimumab) and Renflexis® (infliximab). Organon also has exclusive global commercialisation rights to Bilprevda® and Bildyos®/Tuzemty® (HLX14), biosimilars to Amgen’s Prolia® and Xgeva® (denosumab), and Poherdy® (HLX11), biosimilar to Genentech/Roche’s Perjeta® (pertuzumab), for all countries except China, Hong Kong, Macau and Taiwan, under a June 2022 licence agreement between Organon and Shanghai Henlius Biotech. Bilprevda® and Bildyos® have been approved in the US (September 2025), EU (September 2025), and Canada (March 2026). Poherdy® was approved by the FDA in November 2025 and received a positive CHMP opinion in early 2026.
In March 2026, Sun Pharma launched its generic semaglutide products, Noveltreat™ and Sematrinity™ (semaglutide), in India. The products are indicated for chronic weight management and type 2 diabetes mellitus, respectively.